Abstract
Background: Length of stay after non–ST-segment elevation myocardial infarction (NSTEMI) continues to decrease, but information to guide duration of hospitalization is limited. Methods: We used landmark analyses, in which the landmark defined potential days of discharge, to estimate complication rates on the first day the patient would have been out of the hospital, and estimated associations between timing of discharge and 30-day and 1-year event-free survival after discharge among NSTEMI patients. Results: Among 20,410 NSTEMI patients, median length of stay was 7 (4, 12) days; 3,209 (15.7%) experienced a cardiac complication on days 0 to 2 and 1,322 (6.5%) were discharged without complications during hospital days 0 to 2. At the start of day 3, 15,879 patients (77.8%) were still hospitalized without complications. Of these, 1,689 (10.6%) were discharged event-free on day 3. Adjusted event-free survival rates of death or myocardial infarction from day 4 to 30 days after among the 1,689 patients was 99.1% compared with 93.1% for the 14,190 who remained hospitalized at the end of day 3. For 1-year mortality, these rates were 98.1% and 96.4%, respectively. Among 13,334 patients hospitalized without complications at the start of day 4, 1,706 were discharged event-free that day. Adjusted survival rates among these patients, compared with those still hospitalized at the end of day 4, were 98.0% versus 93.7% for 30-day death or myocardial infarction and 97.8% versus 96.1% for 1-year mortality. Conclusions: Patients with NSTEMI who had no serious complications during the first 2 hospital days were at low risk of subsequent short- and intermediate-term death or ischemic events.
| Original language | English |
|---|---|
| Pages (from-to) | 103-110 |
| Number of pages | 8 |
| Journal | American Heart Journal |
| Volume | 201 |
| DOIs | |
| State | Published - Jul 2018 |
Bibliographical note
Publisher Copyright:© 2018
Funding
Dr Rymer, Dr Templehof, Mr Clare, Ms Pieper, Dr Granger, and Dr Moliterno have no relevant conflicts of interest. Dr Van de Werf reports research grants from Merck, and advisory board membership, DSMB, and lecture fees from Merck. Harrington reports research grants from Merck, Astra, BMS, J&J, and consulting honoraria from CSL, BMS, Daiichi, Gilead, J&J, Merck, and MyoKardia. Dr White reports research grants from Sanofi Aventis, Eli Lilly, Medicines Company, NIH, Roche, Merck Sharpe & Dohme, Astra Zeneca, GSK, and Daiichi Sankyo Pharma Development, as well as consulting from Astra Zeneca, Merck Sharpe & Dohme, Roche, and Regado Biosciences. Dr Armstrong reports research grants from Merck & Company, and consulting honoraria from Eli Lilly. Dr Lopes reports research grants from BMS, Pfizer, Bayer, Jansen, and Astra-Zeneca. Dr Mahaffey reports research grants from AstraZeneca, Boehringer Ingleheim, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Portola, Regado Biotechnologies, Sanofi, Schering-Plough (now Merck), and The Medicines Company, as well as consulting honoraria from Bayer, Daiichi Sankyo, and Johnson & Johnson. Dr Newby reports no relevant conflicts of interest. Her relationships with industry are reported at: https://www.dcri.org/about-us/conflict-of-interest . This work was supported in part by a Barton F. Haynes Resident Research Award, Department of Medicine, Duke University Medical Center, and from academic discretionary resources of the senior investigator. Dr Rymer was supported by a training grant to Duke University from the National Heart Lung and Blood Institute (5 T32 HL 69749).
| Funders | Funder number |
|---|---|
| Astra Zeneca Inc | |
| College of Medicine, Department of Medicine | |
| Medicines Company | |
| Merck Sharpe & Dohme | |
| Merck Sharpe & Dohme, Roche, and Regado Biosciences | |
| Sanofi Aventis | |
| National Institutes of Health (NIH) | |
| National Heart, Lung, and Blood Institute (NHLBI) | T32HL069749 |
| Eli Lilly and Company | |
| Roche Diagnostics | |
| Duke-Kunshan University | |
| North Carolina GlaxoSmithKline Foundation | |
| Daiichi Sankyo Company, Limited |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine